Results 151 to 160 of about 4,234 (179)

PPTP: Pre-Post Terminal Propagation in modern fixed-outline soft module VLSI floorplanning design

2012 10th IEEE International Conference on Semiconductor Electronics (ICSE), 2012
From the point of view of the industry, floorplanning is very important in VLSI chip physical design because it will deeply affect the time-to-market and the quality of the product. A new floorplanning algorithm namely Pre-Post Terminal Propagation (PPTP) has been proposed to handle soft module floorplanning by employing multilevel framework.
Chyi-Shiang Hoo, Harikrishnan Ramiah
exaly   +2 more sources

Analysis and implementation of man-in-the-middle attack on Microsoft's PPTP

International Conference on Cryptography, Network Security, and Communication Technology (CNSCT 2022), 2022
exaly   +2 more sources

Cryptanalysis of Microsoft's point-to-point tunneling protocol (PPTP)

Proceedings of the 5th ACM conference on Computer and communications security, 1998
The Point-to-Point Tunneling Protocol (PPTP) is used to secure PPP connections over TCP/IP links. In this paper we analyze Microsoft’s Windows NT implementation of PPTP. We show how to break both the challenge/response authentication protocol (Microsoft CHAP) and the RC4 encryption protocol (MPPE), as well as how to attack the control channel in ...
Bruce Schneier, null Mudge
openaire   +1 more source

Breaking PPTP VPNs via RADIUS Encryption

2016
We describe an efficient cross-protocol attack, which enables an attacker to learn the VPN session key shared between a victim client and a VPN endpoint. The attack recovers the key which is used to encrypt and authenticate VPN traffic. It leverages a weakness of the RADIUS protocol executed between a VPN endpoint and a RADIUS server, and allows an ...
Matthias Horst, Martin Grothe, Tibor Jager, Jörg Schwenk   +3 more
openaire   +1 more source

345 Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin

European Journal of Cancer, 2012
• PD2 (Progressive Disease 2): >25% ↑ in tumor volume, TGD value >1.5; • SD (Stable Disease): 2.0 Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of ...
M. Smith, M. Kang, R. Lock, H. Carol, R. Gorlick, A. Kolb, J. Maris, S. Keir, R. Kurmasheva, P. Houghton   +9 more
openaire   +1 more source

Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A

Journal of Clinical Oncology, 2009
10015 Background: GSK923295A is a small molecule inhibitor of centromere-associated protein E (CENP-E), a mitotic kinesin that is required for metaphase chromosome alignment and integration of mitotic spindle mechanics with mitotic checkpoint signaling. An initial phase I clinical trial in adults is ongoing.
M. A. Smith, C. L. Morton, H. Carol, R. G. Gorlick, M. H. Kang, S. T. Keir, E. A. Kolb, R. B. Lock, J. M. Maris, P. J. Houghton   +9 more
openaire   +1 more source

Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.

Cancer Research, 2013
Abstract Introduction: Cabozantinib is an oral, small-molecule inhibitor of MET, VEGFR2, and RET, and it also inhibits AXL, KIT and TIE-2. These targets are known to play important roles in tumor cell proliferation and/or angiogenesis.
Malcolm Smith, Min Kang, Patrick Reynolds, Richard Gorlick, Anders Kolb, John Maris, Stephen Keir, Catherine Billups, Raushan Kurmasheva, Peter Houghton   +9 more
openaire   +1 more source

Abstract C207: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of Glembatumumab Vedotin.

Molecular Cancer Therapeutics, 2013
Abstract Introduction: Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein NMB (GPNMB, also known as osteoactivin, dc-HIL, and HGFIN). Because of the restrictive expression of GPNMB, testing was limited to the PPTP osteosarcoma (OS) xenograft panel as well as two non ...
Richard Gorlick, Anders Kolb, Jainrong Wu, Raushan Kurmasheva, Thomas Hawthorne, Peter Houghton, Malcolm Smith   +6 more
openaire   +1 more source

Abstract 5266: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965

Cancer Research, 2010
Abstract Background: SCH 727965 is a potent inhibitor of CDK1, CDK2 and CDK9 activities in vitro and has been shown to be effective as a single agent against a wide-spectrum of adult tumor xenograft models including lung, prostate, breast, ovarian and multiple myeloma, with tumor growth inhibition from 12% to 150% (regression) noted. The
Malcolm A. Smith, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Kier, Richard B. Lock, Hernan Carol, Richard Gorlick, E Anders Kolb, Min Kang, Christopher Patrick Reynolds, Christopher L. Morton, Peter J. Houghton   +12 more
openaire   +1 more source

Abstract LB-318: Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480

Cancer Research, 2012
Abstract Background: AZD1480 is a potent, competitive small molecule inhibitor of JAK1/2 kinase that has entered clinical evaluation. JAK inhibition is of particular pediatric interest given the activating JAK1/2 mutations observed in a subset of pediatric ALL cases.
Hernan Carol, Richard Lock, John Maris, Stephen Keir, Richard Gorlick, Anders Kolb, Min Kang, Patrick Reynolds, Jianrong Wu, Raushan Kurmasheva, Peter Houghton, Malcolm Smith   +11 more
openaire   +1 more source